A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
26 Aug 2024: Trial registered, NCT06571734
19 Sep 2024: Trial started, NCT06571734
The trials
NCT06571734: XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
State
Under way
Phase
Phase 2
People
73 planned
Started
19 Sep 2024
Primary completion
1 Jul 2028
Arms
Treatment (XL092)
Results
None posted
26 Aug 2024: Trial registered
19 Sep 2024: Trial started
How the status changed
19 Nov 2026: First set: Phase 2 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.